-
Mashup Score: 47
This meta-analysis report that GLP1-RA and SGLT2i reduced with a similar efficacy not only MACE as MI, but also cardiovascular mortality and all-cause mortality at a median 3-year follow-up. SGLT2i were more protective in HFH and WRF than GLP1RA. These new data highlight the efficacy of SGLT2i not o …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 15
This meta-analysis report that GLP1-RA and SGLT2i reduced with a similar efficacy not only MACE as MI, but also cardiovascular mortality and all-cause mortality at a median 3 years follow-up. SGLT2i were more protective in HFH and WRF than GLP1RA. These new data highlight the efficacy of SGLT2i not …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
RT @SABOURETCardio: Comparing benefits from #SGLT2i and #GLP1RA #MA https://t.co/oalIaXGYxi
-
-
Mashup Score: 5
GLP-1RAs, precisely longer acting formulations, reduced ischemic cerebrovascular events in T2DM. Observed benefits were significantly higher in patients with shorter T2DM duration and higher eGFR.
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
RT @SABOURETCardio: #GLP1RA and Risk of #stroke in #T2D: A #MA https://t.co/xStOn5fEKo
-
-
Mashup Score: 6
GLP-1RAs, precisely longer acting formulations, reduced ischemic cerebrovascular events in T2DM. Observed benefits were significantly higher in patients with shorter T2DM duration and higher eGFR.
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
#GLP1RA and Risk of #stroke in #T2D: A #MA https://t.co/xStOn5fEKo
-
-
Mashup Score: 5
This meta-analysis report that GLP1-RA and SGLT2i reduced with a similar efficacy not only MACE as MI, but also cardiovascular mortality and all-cause mortality at a median 3 years follow-up. SGLT2i were more protective in HFH and WRF than GLP1RA. These new data highlight the efficacy of SGLT2i not …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
Comparing benefits from #SGLT2i and #GLP1RA #MA https://t.co/oalIaXGYxi
-
-
Mashup Score: 15
No abstract present.
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
New anti-diabetic agents: major advances with unanswered questions. #GLP1RA #SGLT2i #T2D https://t.co/h9wbN34cZq
-
-
Mashup Score: 0
Background: Several clinical trials have demonstrated that glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) reduce the incidence of non-fatal myocardial infarction (MI) in patients with type 2 diabetes mellitus (T2DM). However, the underlying …
Source: PubMed Central (PMC)Categories: Cardiologists, Latest HeadlinesTweet-
#T2D Systematic investigation of the underlying mechanisms of #GLP1RA to prevent #MI https://t.co/re9yJ2UOk6
-
-
Mashup Score: 3Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials - 1 year(s) ago
This genome-wide pharmacogenomic study of GLP-1 receptor agonists provides novel biological and clinical insights. Clinically, when genotype is routinely available at the point of prescribing, individuals with ARRB1 variants might benefit from earlier initiation of GLP-1 receptor agonists.
Categories: Endocrinology, Latest HeadlinesTweet-
"Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials" Read the full paper by Dawed et al here: https://t.co/Fx43SzfoiA #GLP1RA
-
-
Mashup Score: 4Des nouveautés dans le diabète de type 2 - 1 year(s) ago
a classe des iSGLT2 a suscité un enthousiasme énorme dans la communauté cardiologique en raison de ses bénéfices dans l’insuffisance cardiaque à fraction d’éjection altérée puis dans l’insuffisance cardiaque à fraction d’éjection préservée, et plus récemment dans l’insuffisance rénale. Ces bénéfices cardio-rénaux sont observés que les patients soient diabétiques ou non. Certains experts ont donc…
Source: Cardiologie PratiqueCategories: Cardiologists, Latest HeadlinesTweet-
https://t.co/DLraAIomUc my article in French summarising the last data on #SGLT2i and #GLP1RA during @CNCFCardio congress
-
-
Mashup Score: 0
Author links open overlay panelKey Wordsacute coronary syndromepredictive utilityprognostic utilityDr. Narula has received grant support (in the form of equipment to his institution) from GE and Philips Healthcare. Dr. Kaul has reported that he has no relationships relevant to the contents of this paper to disclose.∗Editorials published in the Journal of the American College of Cardiology reflect…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet-
In Search of the #VulnerablePlaque : Is There Any Light at the End of the Catheter? #LLT #GLP1RA #PCSK9i https://t.co/AFhEP6dx14
-
Comparing benefits from #SGLT2i and #GLP1RA : a #MA https://t.co/oalIaXGYxi